← Leaderboards
Patricia R Taylor
Case Western Reserve University
$2,093,857
Attributed
$2,093,857
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $402.5K · FY2012–25$500K$375K$250K$125K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,093,857 · 2
VA$0 · 3
By mechanism
R01$1,987,725 · 1
F32$106,132 · 1
I01$0 · 2
IK2$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- Jessica Marie Perez$86,892
- Koc Omer$157,740
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingCellsProductionBlindnessDiabeticNovel TherapeuticsCytokineInflammatoryPathogenesisDiabetes MellitusRetinaInflammationOxidative StressDiabetic RetinopathyRetinal DiseasesMouse ModelDiabetic MousePrediabetes SyndromeProteinsChronicBlood CapillariesPathologicComplications Of Diabetes MellitusInterleukins
Grant awards (18)
The role of STEAP4 in retinal pathogenesis and diabetic retinopathy$0
I01 · FY2025 · VA · contact PI
Identification of Immunomodulators for Diabetic Retinopathy Therapeutics$402,500
R01 · FY2024 · EY · contact PI
The role of STEAP4 in retinal pathogenesis and diabetic retinopathy$0
I01 · FY2024 · VA · contact PI
The role of IL-17A in the onset and progression of diabetic retinopathy in VA patients$0
I01 · FY2024 · VA · contact PI
Identification of Immunomodulators for Diabetic Retinopathy Therapeutics$402,500
R01 · FY2023 · EY · contact PI
The role of IL-17A in the onset and progression of diabetic retinopathy in VA patients$0
I01 · FY2023 · VA · contact PI
Identification of Immunomodulators for Diabetic Retinopathy Therapeutics$390,425
R01 · FY2022 · EY · contact PI
The role of IL-17A in the onset and progression of diabetic retinopathy in VA patients$0
I01 · FY2022 · VA · contact PI
Identification of Immunomodulators for Diabetic Retinopathy Therapeutics$390,425
R01 · FY2021 · EY · contact PI
The role of IL-17A in the onset and progression of diabetic retinopathy in VA patients$0
I01 · FY2021 · VA · contact PI
Identification of Immunomodulators for Diabetic Retinopathy Therapeutics$401,875
R01 · FY2020 · EY · contact PI
The role of IL-17 neutrophils and lymphocytes during diabetic retinopathy$0
IK2 · FY2020 · VA · contact PI
The role of IL-17 neutrophils and lymphocytes during diabetic retinopathy$0
IK2 · FY2019 · VA · contact PI
The role of IL-17 neutrophils and lymphocytes during diabetic retinopathy$0
IK2 · FY2018 · VA · contact PI
The role of IL-17 neutrophils and lymphocytes during diabetic retinopathy$0
IK2 · FY2017 · VA · contact PI
The role of IL-17 neutrophils and lymphocytes during diabetic retinopathy$0
IK2 · FY2016 · VA · contact PI
The Role of IL-17 in fungal keratitis$53,942
F32 · FY2013 · EY · contact PI
The Role of IL-17 in fungal keratitis$52,190
F32 · FY2012 · EY · contact PI